multiple sclerosis(13) COVID-19(4) Alemtuzumab(3) Safety(3) Disease-modifying therapies(3) antibodies(2) vaccination(2) Disease-modifying therapy(2) sphingosine 1-phosphate receptor modulators(2) COVID-19 outcomes(2) Pregnancy(1) product surveillance(1) T-cell Response(1) Real world(1) Cladribine(1) S1P modulators(1) monoclonal antibody(1) dimethyl fumarate(1) Ozanimod(1) fingolimod(1) Ofatumumab(1) Risk factors(1) infections(1) Multiple sclerosis (MS)(1) Bruton’s tyrosine kinase(1) omicron(1) disease-modifying drug(1) Efficacy(1) Relapsing-Remitting Multiple Sclerosis(1) adverse events(1)